Medela LLC has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for ENFit Low Dose Tip enteral syringes market

 

Growing cases of critical care and neonatal intensive care unit admissions are propelling the growth of the global enteral syringe market. According to statistics given by Bliss Organization, over 95,000 newborns are admitted to neonatal units in the U.K, annually due to premature birth (before 37 weeks of pregnancy) or due to full term (after 37 weeks) yet sick birth. Moreover, according to the same source around 1 in every 8 newborns in the U.K are admitted to neonatal units, annually. The increasing geriatric population around the globe is again augmenting the growth of the market. According to the United Nation, the global population aged 60 years or over numbered 962 million in 2017, the number of older persons is expected to double again by 2050, when it is projected to reach nearly 2.1 billion.

North America is expected to dominate the global enteral syringe market and this is attributed to the continuous launch of the innovative product by key players in the region. For instance, in February 2017, Baxter International Inc. a global provider of nutrition therapy announced the expansion of its nutrition care portfolio to include the new enteral ENFit® syringe and accessory line for patients requiring tube feeding in the United States during the American Society of Parenteral and Enteral Nutrition’s (ASPEN) Clinical Nutrition Week (CNW) conference.

In March 2017, Medela LLC has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market ENFit Low Dose Tip enteral syringes. The ENFit Low Dose Tip can help to deliver accurate doses while reducing the risk of misconnections
In July 2017, Gerresheimer will complete its product portfolio of prefillable syringes made of glass and plastics with an innovative, integrated, passive syringe safety solution, acquired through an exclusive license from West Pharmaceutical Services, Inc.
In June 2019, NeoMed has launched NeoConnect at Home, a reusable portfolio of ENFit syringes that do not require a physician’s prescription.
Key players operating in the global enteral syringe market include GBUK Enteral Ltd., Thermo Fischer, Inc., B. Braun Melsungen AG, Koninklijke Philips N.V., Miktell Ltd., Baxter International, Inc., Cardinal Health, Inc., Terumo Corporation, Kentec Medical, Inc., Vygon S.A., and others.

Enteral Syringes are designed to deliver nutrition to the body quickly. The syringe contains two removable plastic tubes, one tube is inserted into the mouth of the patient. The tube then travels down the drainage path until it reaches the cannula which is used to administer the medication. The tubes are then inserted back into the mouth so that the medication can be delivered directly to the intestines.